Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

A randomized, double-blind, placebo-controlled clinical trial will be conducted at Hospital de Clínicas de Porto Alegre (HCPA), Brazil. A total of 94 participants with DM2 will be recruited and randomized on a 1:1 ratio to receive 3 g taurine as a powder for oral suspension, twice per day, for 12 weeks or packets containing placebo. Blood will be collected prior to the treatment and after 12 weeks for glycated hemoglobin, fasting glucose, insulinemia, total cholesterol and fractions, triglycerides, C-reactive protein, creatinine, urea, tumor necrosis factor-alpha (TNF-α), interleukin 1 and 6 (IL-1 and IL-6) measures. Urine will be collected at baseline and after 12 weeks for creatine, protein, and albumin measured. Anthropometric parameters and a 24-h dietary recall will be monthly investigated. Fourteen days before the end of the trial, participants will be connected to a continuous glucose monitoring system for glucose monitoring system for glucose variability evaluation. Participants will be contacted by phone weekly to report adverse effects.

Inclusion criteria

• Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;
• Age over 30 years;
• BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;
• HbA1c between 7.5% and 10.5%.

Exclusion criteria

• Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;
• Pregnancy or lactation;
• Chronic renal failure with glomerular filtration rate calculated by MDRD < 30 mL/h;
• Myocardial infarction in the last than 6 months
• Current neoplasia;
• Chronic use of glucocorticoids;
• Bariatric surgery.